Advert for Healthcare Professionals Only
I am a patient (Please go to our patient website)
- All Topics
- Allergy and Clinical Immunology
- Anesthesiology
- Angiology
- Cardiology
- Central Nervous System
- Clinical Laboratory
- Complementary and Alternative Medicine
- Critical Care/Intensive Care
- Dermatology
- Diabetes and Endocrinology
- Ear, Nose and Throat
- Emergency Medicine
- Eye Health and Disorders
- Family Medicine
- Gastroenterology
- Gerontology/Geriatrics
- Haematology
- Hepatology
- HIV/AIDS
- Immunology
- Infectious Diseases
- Internal Medicine
- Kidney and Urological Diseases
- Medical Genetics
- Men's Health, Andrology and Urology
- Musculoskeletal Disorders
- Neonatal/Perinatal Medicine
- Neurological Disorders
- Nutrition and Dietetics
- Oncology
- Orthopaedics
- Paediatrics
- Pain Management
- Palliative Medicine
- Plastic Surgery and Aesthetic Medicine
- Podiatry
- Preventive Medicine
- Psychiatry/Mental Health
- Radiology
- Respiratory
- Rheumatology
- Sexual Health
- Sleep Medicine
- Sports Medicine
- Surgery (General)
- Transplantation
- Tropical Medicine
- Vaccines
- Women's Health and Obs/Gyn
- ADHD
- Alzheimer's Disease
- Arthritis
- Atopic Dermatitis
- Cholesterol
- Chronic Myeloid Leukemia
- COPD
- Cystic Fibrosis
- Diabetes
- Gastrointestinal Stromal Tumours
- Hepatitis
- Hypertension
- Insomnia
- Lysosomal Storage Disorders
- Men's Health
- Multiple Sclerosis
- Niemann-Pick type C
- NSCLC
- Opioids and Pain
- Parkinson's Disease
- Post-Myocardial Infarction
- Prostate Cancer
- Renal Anaemia
- Renal Cell Carcinoma
- Soft Tissue Sarcoma
- Third Party Website - Asthma and COPD
- CAPOZIDE TABLETS
- SURMONTIL 10MG AND 25MG TABLETS
- NAPRATEC OP
- COBALIN-H INJECTION
- CARBEX
- CALCIUM RESONIUM 99.934% W/W POWDER FOR ORAL/RECTAL SUSPENSION
- HYPURIN BOVINE ISOPHANE
- HYPURIN BOVINE LENTE
- HYPURIN PORCINE 30/70 MIX CARTRIDGES
- HYPURIN BOVINE ISOPHANE VIALS
- DUKORAL ORAL CHOLERA VACCINE
- OXYNORM LIQUID 5 MG/5 ML ORAL SOLUTION
- DORZOLAMIDE/TIMOLOL EYE DROPS
- FENOFIBRATE 267MG CAPSULES
- TRACRIUM INJECTION
- EXOCIN
- FRAGMIN - TREATMENT OF VTE
- FLUDARABINE PHOSPHATE 50 MG POWDER FOR SOLUTION FOR INJECTION OR INFUSION
- GABITRIL FILM-COATED TABLETS (5 , 10, 15 MG)
- PROTOPIC 0.03% OINTMENT
- XISMOX 60 XL PROLONGED RELEASE TABLETS
- PALLADONE SR CAPSULES
- ZINERYT
- PURI-NETHOL 50 MG TABLETS
- DAKTACORT OINTMENT
- MYLERAN 2 MG FILM-COATED TABLETS
- NEOTIGASON 10MG CAPSULES
- LEUKERAN TABLETS 2 MG
- LANVIS TABLETS 40 MG
- PROVIGIL 100 MG TABLETS, PROVIGIL 200 MG TABLETS
- ADHD
- Alzheimers
- Anxiety Disorders
- Arthritis
- Asthma
- Avonex
- Breast Cancer
- Cervical Cancer
- Cholesterol
- Colorectal Cancer
- Copaxone
- Depression
- Diabetes
- Erectile Dysfunction
- Extavia
- Hypertension
- Insomnia
- Men's Health
- Meningitis
- Migraine
- Pain Management
- Parkinson's
- Pharma News
- Post-MI
- Pregnancy
- Prostate
- Rebif
- Renal anaemia
- Renal Cell Carcinoma
- Thrombosis
- Thromboembolism
- Tysabri
Advert for Healthcare Professionals Only
Latest Drugs
Central Nervous System Drug Data - A-Z (Espanol)
Drug Class Description
Antiparkinsonianos dopaminergicos: otrosDrug Description
COMPRIMIDOSPresentation
Vía oral:. - Adultos: inicialmente 100 mg 3 veces al día, con ajuste posológico de la dosis de levodopa. Los pacientes que toman más de 600 mg/día de levodopa o con disquinesias de moderadas a graves, requirieron en su mayoría una reducción de la dosis diaria de levodopa (en torno al 30%). Tras el ajuste de la dosis de levodopa puede aumentarse la dosis de tolcapona a 200 mg 3 veces al día, con probable reajuste de la dosis de levodopa. - Insuficiencia hepática moderada: 100 mg tres veces al día. - Normas para la correcta administración: Administrar 3 veces al día. La primera dosis coincidiendo con la primera toma de levodopa, las siguientes dosis 6 y 12 horas más tarde. Los comprimidos se deben tragar enteros, con o sin alimento.Indications
- Parkinson: en combinación con levodopa/benserazida o levodopa/carbidopa, en pacientes que no pueda estabilizarse con levodopa+inhibidor de dopadescarboxilasa, especialmente en aquellos con fluctuaciones que presenten fenómenos de final de la dosis.Child Dosage
No hay experiencia clínica en este grupo de edad.Elderly Dosage
No se han observado efectos adversos específicos en este grupo de edad. No obstante los pacientes geriátricos son más susceptibles a los efectos adversos de la levodopa. Aumenta la incidencia de hipotensión, anorexia, vómitos, ansiedad y confusión.Interactions
- Medicamentos metabolizados por la COMT: Aumento de los niveles plasmáticos benserazida (vigilar posible toxicidad cuando se utilicen dosis de benserazida de 50 mg o superiores). No se ha observado interacción con carbidopa. No se ha evaluado el efecto de tolcapone sobre otros sustratos de la COMT como metildopa, dobutamina, adrenalina, isoprenalina, etc. - Medicamentos metabolizados por el isoenzima CYP2CP (tolbutamida, warfarina): riesgo potencial de alteración de niveles plasmáticos. Se aconseja monitorización del tiempo de protrombina. - Inhibidores de la MAO-A (moclobemida): No se dispone de datos. Usar con precaución. - Inhibidores de la MAO-B (selegilina): evitar dosis elevadas de selegilina. Este medicamento puede interferir con la determinación analítica de: Se han observado aumentos de las concentraciones séricas de alanina aminotransferasa (ALT) hasta 3 veces el límite normal superior (por lo general a las 6-12 semanas). En la mitad de los pacientes retornaron a valores normales sin necesidad de interrumpir el tratamiento).Adverse Reactions
Los más frecuentes son: disquinesia, náuseas, insomnio, anorexia y diarrea (16-18%). La diarrea suele presentarse 2-4 meses después de iniciado el tratamiento y obligó al 5% de los pacientes a la suspensión del tratamiento. Tras la reducción de la dosis o la interrupción del tratamiento se han observado síntomas que podrían asociarse al síndrome neuroléptico maligno. - Alérgicas/Dermatológicas: sudoración (3%). - Digestivas: Frecuentemente, diarrea. Ocasionalmente, estreñimiento, dolor abdominal, dispepsia. - Genitourinarias: coloración amarilla de la orina. - Hepatobiliares: Aumento de transaminasas (ALT). Muy rara vez, hepatitis fulminante (3 casos de 100000 tratados). - Neurológicas/psicológicas: Ocasionalmente, vértigo, cefalea, insomnio, hipoquinesia. - Oculares: xeroftalmia (2-3%). - Respiratorias: Aumento de infecciones del tracto superior, síntomas gripales (2-3%), dolor torácico (2%).Manufacturer
ROCHEDrug Availability
APORTACION REDUCIDA (CICERO)Advert for Healthcare Professionals Only
Related News
TEMSO study for Aubagio in Multiple Sclerosis is published in NEJM Central Nervous System Page
The pivotal Phase III TEMSO study with investigational once-daily oral medication Aubagio (teriflunomide) from Sanofi/Genzyme is published in The New England Journal of Medicine (NEJM). Results showed that teriflunomide at the 14mg dosage significantly reduced the annual relapse rate, reduced disability progressions and improved several magnetic resonance imaging (MRI) measures of disease activity, including new or worsening brain lesions in relapsing, remitting Multiple Sclerosis. Teriflunomide has a well-characterized safety profile, with a similar proportion of trial participants reporting adverse events compared to placebo. Teriflunomide has been filed with the FDA in August of 2011 and the EMA filing is expected in the first quarter of 2012. see Randomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosis Paul O'Connor, M.D., et al for the TEMSO Trial Group N Engl J Med 2011; 365:1293-1303 October 6, 2011.
Tysabri shows benefits in Multiple Sclerosis patients Central Nervous System Page
Patients with Multiple Sclerosis who take anti-inflammatory Tysabri (natalizumab), from Biogen and Elan, for two years showed a reduced risk of experiencing at least one relapse (at 2 years this was reduced by 40%). The study also showed that the number of patients whose disability progressed in the time interval was reduced by 25%. In addition, MRI scans showed evidence that treatment with Tysabri reduced disease activity. Treatment also created some side effects including limb swelling, rigors, vaginal inflammation and menstrual disorders and 2 patients treated with Tysabri for more than 2 years developed Progressive Multifocal Leukoencephalopathy, a rare and often fatal viral disease. In light of this, the researchers recommend further studies. The review was published in The Cochrane Database of Systematic Reviews: "Natalizumab for relapsing remitting multiple sclerosis" by Eugenio Pucci et al. Issue 105 OCT 2011.Tysabri is approved in the USA and EU.
Lemtrada and Aubagio trials to report at ECTRIMS/ACTRIMS congress Central Nervous System Page
Genzyme/Sanofi will report more than 20 abstracts at ECTRIMS/ACTRIMS congress. Data will include Phase III results of Lemtrada(alemutuzumab) and Aubagio ( oral teriflunomide) in relapsing remitting Multiple Sclerosis (MS) including CARE-MS 1 study comparing Lemtrada and Rebif (interferon beta 1-a) in relapsing remitting MS and five year extension of TEMSO study of oral Aubagio (Poster 924) and efficacy of Aubagio (Poster 438) and long term results for Lemtrada CARE-MS Phase II trial (Poster 928) and four year efficacy of Lemtrada in MS (Poster 931). Lemtrada is being developed by Genzyme/Sanofi in the USA and Bayer HealthCare in the EU.
